- Home
- GSBC vs GKOS Comparison
GSBC vs GKOS Comparison
Compare GSBC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- GKOS
- Stock Information
- Founded
- GSBC 1923
- GKOS 1998
- Country
- GSBC United States
- GKOS United States
- Employees
- GSBC N/A
- GKOS N/A
- Industry
- GSBC Major Banks
- GKOS Medical/Dental Instruments
- Sector
- GSBC Finance
- GKOS Health Care
- Exchange
- GSBC Nasdaq
- GKOS Nasdaq
- Market Cap
- GSBC N/A
- GKOS 5.1B
- IPO Year
- GSBC N/A
- GKOS 2015
- Fundamental
- Price
- GSBC $55.90
- GKOS $93.79
- Analyst Decision
- GSBC Hold
- GKOS Strong Buy
- Analyst Count
- GSBC 2
- GKOS 13
- Target Price
- GSBC $59.50
- GKOS $155.00
- AVG Volume (30 Days)
- GSBC 36.5K
- GKOS 1.0M
- Earning Date
- GSBC 04-16-2025
- GKOS 04-30-2025
- Dividend Yield
- GSBC 2.87%
- GKOS N/A
- EPS Growth
- GSBC 10.51
- GKOS N/A
- EPS
- GSBC 5.60
- GKOS N/A
- Revenue
- GSBC $219,572,000.00
- GKOS $383,481,000.00
- Revenue This Year
- GSBC N/A
- GKOS $27.84
- Revenue Next Year
- GSBC $0.33
- GKOS $27.99
- P/E Ratio
- GSBC $9.97
- GKOS N/A
- Revenue Growth
- GSBC N/A
- GKOS 21.85
- 52 Week Low
- GSBC $47.57
- GKOS $77.91
- 52 Week High
- GSBC $68.02
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- GSBC 56.23
- GKOS 46.82
- Support Level
- GSBC $53.88
- GKOS $92.79
- Resistance Level
- GSBC $57.68
- GKOS $97.38
- Average True Range (ATR)
- GSBC 2.09
- GKOS 4.43
- MACD
- GSBC 0.58
- GKOS 1.61
- Stochastic Oscillator
- GSBC 78.73
- GKOS 72.39
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.